CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30

One of the most talked-about moments at this year’s American College of Cardiology Scientific Session was the presentation of the ARTISAN interim analysis by Dr. Raymond Benza — a study that was voted one of the Top 4 abstracts in Pulmonary Hypertension. ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction), is a prospective, multicenter, open-label clinical […]

CardioMEMS-guided therapy shows promising results in pulmonary arterial hypertension: ARTISAN interim analysis presented at the American College of Cardiology Congress 2026, March 28–30 Read Post »

A case report about initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension (IPAH), ERJ Open Research, March 30, 2026

To date sotatercept has only been studied in patients with prevalent pulmonary arterial hypertension receiving stable background therapy, not as part of the initial treatment regimen in newly diagnosed patients. A case report, published recently on the ERJ Open Research, describes a 25-year-old woman who developed severe high-risk idiopathic pulmonary arterial hypertension (IPAH) shortly after

A case report about initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension (IPAH), ERJ Open Research, March 30, 2026 Read Post »

Promising results for nebulised treprostinil (Tyvaso) in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD), WHO Group 3

United Therapeutics reported positive results from TETON-1, its second Phase III trial testing nebulised Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF). The trial, involving 598 patients over 52 weeks, showed that nebulised Tyvaso was superior to placebo in improving forced vital capacity (FVC) by 130.1 mL, and also achieved statistical significance in reducing the risk

Promising results for nebulised treprostinil (Tyvaso) in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD), WHO Group 3 Read Post »

Sotatercept for WHO Group 2 pulmonary hypertension sub-group: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study, Circulation, March 29, 2026

The Phase 2 CADENCE randomised controlled trial tested sotatercept in patients with combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction (CpcPH-HFpEF) — a serious condition with high mortality and no proven treatments (Group 2 WHO pulmonary hypertension classification). 164 patients received either sotatercept (at one of two doses) or placebo

Sotatercept for WHO Group 2 pulmonary hypertension sub-group: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study, Circulation, March 29, 2026 Read Post »

Martine Rothblatt, founder and CEO of United Therapeutics, included in Forbes’ America’s Greatest Innovators list

Martine Aliana Rothblatt (born 1954) is an American lawyer, author, and entrepreneur. She founded United Therapeutics in 1996, to make medicines for her daughter who suffered from pulmonary arterial hypertension, and is now developing genetically modified pig organs for human transplant. On the latter topic she has written a book titled “Your life or mine

Martine Rothblatt, founder and CEO of United Therapeutics, included in Forbes’ America’s Greatest Innovators list Read Post »

Sotatercept in pulmonary arterial hypertension: A step-by-step approach for considering the new kid on the block, CHEST, March 4, 2026

Since sotatercept received Food and Drug Administration (FDA) approval for pulmonary arterial hypertension in March 2024, knowing when and how to use it has become an essential part of managing this serious condition — so say the authors of a recently published article in CHEST, who offer a practical guide for clinicians navigating this new

Sotatercept in pulmonary arterial hypertension: A step-by-step approach for considering the new kid on the block, CHEST, March 4, 2026 Read Post »

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026

This review covers the full clinical picture of pulmonary arterial hypertension (PAH) — from its pathophysiology and diagnosis through to current and emerging treatments. Understanding the Disease Pulmonary arterial hypertension is driven by progressive structural remodelling of the pulmonary arteries, creating a vicious cycle of vasoconstriction, inflammation, and uncontrolled cell growth that ultimately leads to

A Comprehensive literature review on the pathophysiology, mechanism, diagnosis, and management of pulmonary arterial hypertension, US Cardiology Review, January 28, 2026 Read Post »

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026

A Japanese study has confirmed that sotatercept works just as well in Asian patients, even though pulmonary arterial hypertension presents somewhat differently in the Asian population: patients tend to have longer disease duration, more severe baseline profiles, and are more frequently on intensive triple therapy including parenteral prostacyclin. This was a regional Phase 3, open-label

Treatment paradigm shifts in pulmonary arterial hypertension: evidence from a phase 3 study in Asia on sotatercept, JACC, March 3, 2026 Read Post »

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026

A consensus document featuring 10 statements, the main focus of which was the use of parenteral prostanoids, was developed by eight experts in pulmonary arterial hypertension during in-person and web-based meetings. Forty-six Italian physicians were invited online to rate each statement, indicating their agreement, neutrality or disagreement. These consensus statements are intended to support physicians

2025 expert consensus on the use of parenteral prostanoids in incident and prevalent PAH patients: The Italian perspective, Vascular Pharmacology, February 28, 2026 Read Post »

Results of the PROSERA study for seralutinib in pulmonary arterial hypertension released by Gossamer Bio on February 23, 2026

The PROSERA study for seralutinib in pulmonary arterial hypertension findings were released yesterday and report that it did not meet its primary endpoint in the full population. It appears that unexpected placebo results in some geographical areas may have been responsible for this happening. While this is disappointing news for the patient community the program

Results of the PROSERA study for seralutinib in pulmonary arterial hypertension released by Gossamer Bio on February 23, 2026 Read Post »

Phase 3, Open-Label Multicenter Study of Sotatercept in Japanese Participants With Pulmonary Arterial Hypertension, JACC Asia, January 20, 2026

This multicenter, open-label, single-arm phase 3 study aimed to assess the efficacy and safety of sotatercept in Japanese patients with PAH. Forty-six adult Japanese patients with pulmonary arterial hypertension receiving stable background therapy were enrolled in a multicenter, open-label, single-arm phase 3 study to assess the efficacy and safety of sotatercept in Japanese patients. They

Phase 3, Open-Label Multicenter Study of Sotatercept in Japanese Participants With Pulmonary Arterial Hypertension, JACC Asia, January 20, 2026 Read Post »

Should we “hit hard and early” from pulmonary arterial hypertension diagnosis? New study aims to provide the first prospective evidence to answer this crucial question, ERJ Open Research, January 19, 2026

Current joint European Society of Cardiology and European Respiratory Society pulmonary hypertension clinical practice guidelines recommend double oral therapy for intermediate-risk pulmonary arterial hypertension patients . They recommend upfront triple combination therapy for high-risk patients only, but retrospective data suggests triple therapy including parenteral prostacyclins may be better. The phase IV, multicentre, prospective, randomised, two-arm,

Should we “hit hard and early” from pulmonary arterial hypertension diagnosis? New study aims to provide the first prospective evidence to answer this crucial question, ERJ Open Research, January 19, 2026 Read Post »

Exploring the relationship between adherence and outcomes in pulmonary arterial hypertension: A retrospective cohort study in the United States, Respiratory Medicine, January 12, 2026

Research published in Respiratory Medicine on January 12, 2026, explored adherence to pulmonary arterial hypertension-specific therapies across different therapeutic classes, identified factors associated with non-adherence and evaluated its impact on clinical outcomes. Adherence was measured by proportion of days covered (PDC) during the treatment period, defined as 60 days after first therapy until treatment discontinuation/censor.

Exploring the relationship between adherence and outcomes in pulmonary arterial hypertension: A retrospective cohort study in the United States, Respiratory Medicine, January 12, 2026 Read Post »

Durability of sotatercept response in pulmonary arterial hypertension: Insights from extended real-world follow-up, International Journal of Cardiology, January 2, 2026

A retrospective cohort study using data from 103 healthcare organizations compared 454 pulmonary arterial hypertension patients receiving sotatercept to 963.386 pulmonary arterial hypertension patients not receiving sotatercept. After propensity score matching to balance baseline characteristics, 346 patients per group were analyzed over an average follow-up of approximately 6-8 months. The sotatercept group demonstrated dramatically lower

Durability of sotatercept response in pulmonary arterial hypertension: Insights from extended real-world follow-up, International Journal of Cardiology, January 2, 2026 Read Post »

The Discovery of Inhaled Prostanoids for Pulmonary Hypertension, Prof. Werner Seeger, Pulmonary Circulation, December 18, 2025

A very interesting article by Prof. Werner Seeger recounts the discovery and development of inhaled prostanoids for pulmonary hypertension at the Giessen Pulmonary Hypertension center (Germany) in the late 1980s-1990s (§). Initially researching acute lung injury/Acute Respiratory Distress Syndrome (ARDS), researchers at Giessen observed that while intravenous vasodilators worsened ventilation/perfusion mismatch, aerosolized prostacyclin (PGI2) reduced

The Discovery of Inhaled Prostanoids for Pulmonary Hypertension, Prof. Werner Seeger, Pulmonary Circulation, December 18, 2025 Read Post »

Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension, Clinical Respiratory Journal, December 19, 2025

Parenteral prostacyclin therapy remains the cornerstone for high-risk pulmonary arterial hypertension (PAH) patients but is limited by complications and reduced quality of life. A case series of eight high-risk patients demonstrated that adding sotatercept successfully enabled transition from intravenous to oral prostacyclin therapy. All patients received background dual therapy with endothelin receptor antagonists and phosphodiesterase-5

Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension, Clinical Respiratory Journal, December 19, 2025 Read Post »

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025

This is a small study but it addresses a very important but often overlooked issue, that of injection site pain for pulmonary arterial hypertension patients being treated with sub-cutaneous treprostinil, which can significantly affect quality of life. The researchers found that topical 10% lidocaine gel provided rapid and effective relief of injection site pain, facilitating

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025 Read Post »

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease where early detection is strongly encouraged to prevent irreversible vascular and cardiac damage. However, a fundamental paradox exists: while clinicians are urged to diagnose pulmonary arterial hypertension early, treatment is restricted to symptomatic patients (New York Heart Association (NYHA) functional class II or higher), leaving asymptomatic

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025 Read Post »

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories, Pulmonary Circulation, November 11, 2025

Access to specialized care may differ between urban and rural patients, potentially influencing outcomes. A study conducted at the at the University of Utah Pulmonary Hypertension Center compared 263 pulmonary arterial hypertension patients from urban versus rural areas treated in the period 2020-2024. Similar at baseline: Important differences emerged: Conclusion: Despite similar care delivery and

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories, Pulmonary Circulation, November 11, 2025 Read Post »

Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis, Frontiers in Medicine, October 2025

A network meta-analysis conducted by researchers at the Cleveland Clinic Abu Dhabi, published in the October 2025 edition of Frontiers in Medicine, compared the efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension (PAH) by synthesizing data from 32 studies, comprising 24 randomised controlled trials, three open-label trials,and five cohort studies, with a cumulative

Comparative efficacy and safety of prostacyclin therapies for pulmonary arterial hypertension: a systematic review and network meta-analysis, Frontiers in Medicine, October 2025 Read Post »

TRANSLATE »
Scroll to Top